Download PDF
Thromb Haemost 1991; 65(04): 415-420
DOI: 10.1055/s-0038-1648163
Original Article
Schattauer GmbH Stuttgart

MCI–9042, a New Antiplatelet Agent Is a Selective S2-Serotonergic Receptor Antagonist

H Hara
Pharmaceuticals Laboratory Research Center, Mitsubishi Kasei Corporation, Yokohama, Japan
,
M Osakabe
Pharmaceuticals Laboratory Research Center, Mitsubishi Kasei Corporation, Yokohama, Japan
,
A Kitajima
Pharmaceuticals Laboratory Research Center, Mitsubishi Kasei Corporation, Yokohama, Japan
,
Y Tamao
Pharmaceuticals Laboratory Research Center, Mitsubishi Kasei Corporation, Yokohama, Japan
,
R Kikumoto
Pharmaceuticals Laboratory Research Center, Mitsubishi Kasei Corporation, Yokohama, Japan
› Author Affiliations
Further Information

Publication History

Received: 02 July 1990

Accepted after revision 26 November 1990

Publication Date:
02 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

MCI–9042, (±)–1–[2–[2–(3–methoxyphenyl)ethyl]phenoxy]–3–(dimethylamino)–2–propyl hydrogen succinate hydrochloride inhibited platelet aggregation induced by collagen and secondary aggregation by ADP or epinephrine at 10−6 M level in platelets of various species. The antiplatelet effect of MCI–9042 was potentiated in aggregation induced by a combination of serotonin with collagen. IC50 value of human platelet aggregation by the serotonin plus collagen was 1.0 × 10−7 M. MCI–9042 inhibited serotonin release accompanied with collagen-induced platelet aggregation, while it did not affect serotonin uptake into platelet. MCI–9042 also potently inhibited the S2-serotonergic receptor-mediated contraction of rat caudal artery by serotonin in a competitive manner with a Ki value of 1.79 × 10–8 M, while Si receptor- or adrenergic receptor-mediated vasoconstriction was inhibited more weakly. Platelet adhesiveness, c-AMP level in platelets and the conversion of arachidonic acid to thromboxane A2 were not influenced by MCI–9042. These results suggest that MCI–9042 is a selective S2-serotonergic receptor antagonist, exhibiting the inhibition of S2-serotonergic potentiated platelet aggregation and the suppression of blood vessel constriction mediated by S2-serotonergic receptor.

 

  • References

  • 1 Hara H, Osakabe M, Kitajima A, Tamao Y, Kikumoto R. A novel anti-platelet agent, MCI–9042: a selective S2-serotonergic antagonist. Thromb Haemostas 1989 62. 407 (Abstr)
    PubMedGoogle Scholar
  • 2 Kikumoto R, Hara H, Ninomiya K, Osakabe M, Sugano M, Fukami H, Tamao Y. Synthesis and platelet aggregation inhibitory and antithrombotic properties of (ω-aminoalkoxy)phenylethyl-benzenes. J Med Chem 1990; 33: 1818-1823
    CrossrefPubMedGoogle Scholar
  • 3 Stoltz JF. Uptake and storage of serotonin by platelets. In: Serotonin and the Cardiovascular System Vanhoutte PM. (ed) Raven Press; New York: 1985. pp 37-42
  • 4 Holmsen H. Platelet activation and serotonin. In: Serotonin and the Cardiovascular System Vanhoutte PM. (ed). Raven Press; New York: 1985. pp 75-86
  • 5 De Clerck F, David JL, Janssen PAJ. Serotonergic amplification mechanisms in blood platelets. In: 5–Hydroxytryptamine in Peripheral Reactions De Clerck F, Vanhoutte PM. (eds). Raven Press; New York: 1982. pp 83-94
  • 6 De Clerck F, Herman AG. 5–Hydroxytryptamine and platelet aggregation. Fed Proc 1983; 42: 228-232
    PubMedGoogle Scholar
  • 7 McGoon MD, Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5–hydroxytryptamine. J Clin Invest 1984; 74: 828-833
    CrossrefPubMedGoogle Scholar
  • 8 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 143-155
    PubMedGoogle Scholar
  • 9 Finney DJ. Probit Analysis. Cambridge University Press; London: 1961. pp 236-254
  • 10 Van Nueten JM, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM. Vascular effect of ketanserin (R41468), a novel antagonist of 5–HT2 serotonergic receptor. J Pharmacol Exp Ther 1981; 218: 217-230
    PubMedGoogle Scholar
  • 11 Cheng YC, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108
    CrossrefPubMedGoogle Scholar
  • 12 White JG. A biphasic response of platelets to serotonin. Scand J Haematol 1970; 7: 145-151
    PubMedGoogle Scholar
  • 13 De Clerck F, David JL, Janssen PAJ. Inhibition of 5–hydroxytrypt-amine-induced and amplified human platelet aggregation by ketanserin (R 41468), a selective 5–HT2 receptor antagonist. Agents Actions 1982; 12: 388-397
    CrossrefPubMedGoogle Scholar
  • 14 Remy DC, Raab AW, Rittle KE, Engelhardt EL, Scriabine A, Lotti VJ. A comparison of the anti serotonin anti histamine and anti cholinergic activity of cyproheptadine with analogs having furan nuclei fused to the 10,11 vinylene bridge. J Med Chem 1977; 20: 836-838
    CrossrefPubMedGoogle Scholar
  • 15 Van Nueten JM, Janssen WJ, Vanhoutte PM. Serotonin and vascular smooth muscle. In: Serotonin and the Cardiovascular System Vanhoutte PM. (ed). Raven Press; New York: 1985. pp 95-103
  • 16 Van Nueten JM, Vanhoutte PM. Selectivity of calcium antagonism and serotonin antagonism with respect to various and arterial tissues. Angiology 1981; 32: 476-484
    CrossrefPubMedGoogle Scholar
  • 17 De Clerck F, Beetens J, De Chaffoy de CourcellesD, Freyne E, Janssen PAJ. R68070: Thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule - I. Biochemical profile in vitro. Thromb Haemostas 1989 61. 35-42
    PubMedGoogle Scholar
  • 18 Hornby EJ, Foster MR, McCabe PJ, Stratton LE. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion. Thromb Haemostas 1989; 61: 429-436
    PubMedGoogle Scholar
  • 19 Saniabadi AR, Lowe GDO, Belch JJF, Barbenel JC, Forbes CD. Effect of prostacyclin(epoprostenol) on the aggregation of human platelets in whole blood in vitro. Haemostasis 1984; 14: 487-494
    PubMedGoogle Scholar
  • 20 Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T, Saitoh Y. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther 1979; 211: 26-30
    PubMedGoogle Scholar
  • 21 Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneim-Forsch 1985; 35: 1144-1149
    PubMedGoogle Scholar
  • 22 Leysen JE. Problems in in vitro receptor binding studies and identification and role of serotonin receptor sites. Neuropharmacology 1984; 23: 247-254
    CrossrefPubMedGoogle Scholar
  • 23 De Clerck F, Xhonneux B. Effect of ketanserin a selective 5–hydroxytryptamine–2 serotonergic antagonist on the secondary recruitment of human platelets in vitro. Agents Actions 1986; 17: 515-526
    CrossrefPubMedGoogle Scholar
  • 24 Bevan J, Heptinstall S. Effect of ketanserin and mepyramine on platelet aggregation and on the uptake of 5–hydroxytryptamine into platelets. Thromb Res 1983; 30: 415-414
    CrossrefPubMedGoogle Scholar
  • 25 Mills DCB, Roberts GCK. Membrane active drugs and the aggregation of human platelets. Nature 1967; 213: 35-38
    CrossrefPubMedGoogle Scholar
  • 26 Cohen RA, Shepherd JT, Vanhoutte PM. 5–Hydroxytryptamine can mediate endothelium-dependent relaxation of coronary arteries. Am J Physiol 1983; 245: H1077-1080
    PubMedGoogle Scholar
  • 27 Cohen RA, Shepherd JT, Vanhoutte PM. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science 1983; 221: 273-274
    CrossrefPubMedGoogle Scholar
  • 28 Laubscher A, Pletscher A. Shape change and uptake of 5–hydroxytryptamine in human blood platelets: Action of neuropsychotropic drugs. Life Sci 1979; 24: 1833-1840
    CrossrefPubMedGoogle Scholar
  • 29 Kitajima A, Hara H, Tamao Y, Kikumoto R. Anti-thrombotic effect of MCI–9042 in experimental thrombosis models. Thromb Haemostas 1989 62. 407 (Abstr)
    PubMedGoogle Scholar